Literature DB >> 18702695

Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.

Peter Koson1, Norbert Zilka, Andrej Kovac, Branislav Kovacech, Miroslava Korenova, Peter Filipcik, Michal Novak.   

Abstract

We have previously demonstrated in a transgenic rat model of tauopathy that human misfolded truncated tau derived from Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. We employed this model to investigate the impact of truncated tau expression levels on life span, neuronal loss and the final load of neurofibrillary tangles (NFTs) in transgenic rats. Two independent transgenic lines (SHR72, SHR318), that display different expression levels of truncated tau, were utilized in this study. We found that transgene expression levels in the brain of SHR72 rats were 44% higher than in SHR318 rats and that truncated tau protein levels determined the survival rate of transgenic rats. The line with higher expression levels of truncated tau (SHR72) showed decreased median survival (222.5 days) when compared with the line with lower expression (SHR318; 294.5 days). Interestingly, NFT loads (total NFT/total neurons) were very similar in terminal stages of disease in both transgenic lines (SHR72 - 10.9%; SHR318 - 11.6%), despite significantly different expression levels of truncated tau. Moreover, mean neuron numbers in the hippocampus (CA1-3) and brain stem (gigantocellular reticular nucleus) in the two transgenic rat strains in the terminal stages of disease were similar, and did not differ significantly from those observed in age-matched non-transgenic controls. These findings suggest that the expression levels of misfolded truncated tau determine the life span in a transgenic rat model of tauopathy without causing neuronal loss or correlating with terminal NFT load.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18702695     DOI: 10.1111/j.1460-9568.2008.06329.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  34 in total

1.  CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.

Authors:  Norbert Zilka; Miroslava Korenova; Branislav Kovacech; Khalid Iqbal; Michal Novak
Journal:  Acta Neuropathol       Date:  2010-04-09       Impact factor: 17.088

2.  Stress-Induced Alterations of Immune Profile in Animals Suffering by Tau Protein-Driven Neurodegeneration.

Authors:  Petr Novak; Martin Cente; Nina Kosikova; Tomas Augustin; Richard Kvetnansky; Michal Novak; Peter Filipcik
Journal:  Cell Mol Neurobiol       Date:  2017-04-12       Impact factor: 5.046

3.  Cortical and hippocampal neurons from truncated tau transgenic rat express multiple markers of neurodegeneration.

Authors:  Peter Filipcik; Martin Cente; Gabriela Krajciova; Ivo Vanicky; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

Review 4.  Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.

Authors:  Thimmappa S Anekonda; Joseph F Quinn
Journal:  Biochim Biophys Acta       Date:  2011-09-08

Review 5.  Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies.

Authors:  Miroslava Korenova; Zuzana Stozicka
Journal:  Cell Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.046

6.  Response of ependymal progenitors to spinal cord injury or enhanced physical activity in adult rat.

Authors:  Dasa Cizkova; Miriam Nagyova; Lucia Slovinska; Ivana Novotna; Jozef Radonak; Milan Cizek; Eva Mechirova; Zoltan Tomori; Jana Hlucilova; Jan Motlik; Igor Sulla; Ivo Vanicky
Journal:  Cell Mol Neurobiol       Date:  2009-04-07       Impact factor: 5.046

Review 7.  Beyond the rat models of human neurodegenerative disorders.

Authors:  Ondrej Bugos; Mangesh Bhide; Norbert Zilka
Journal:  Cell Mol Neurobiol       Date:  2009-03-05       Impact factor: 5.046

Review 8.  New age of neuroproteomics in Alzheimer's disease research.

Authors:  Branislav Kovacech; Norbert Zilka; Michal Novak
Journal:  Cell Mol Neurobiol       Date:  2009-02-19       Impact factor: 5.046

9.  Genomic background-related activation of microglia and reduced β-amyloidosis in a mouse model of Alzheimer's disease.

Authors:  Christina Fröhlich; Kristin Paarmann; Johannes Steffen; Jan Stenzel; Markus Krohn; Hans-Jochen Heinze; Jens Pahnke
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2013-03-01

10.  Animal models for Alzheimer's disease and frontotemporal dementia: a perspective.

Authors:  Jürgen Götz; Naeman N Götz
Journal:  ASN Neuro       Date:  2009-11-09       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.